UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma

Andrea Kokorovic, Surena F Matin, Andrea Kokorovic, Surena F Matin

Abstract

Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The standard treatment for localized high-risk disease is radical nephroureterectomy, which confers significant morbidity and is not appropriate for all patients. Patients harboring low-risk, non-invasive disease may be candidates for organ-sparing treatment, which includes endoscopic resection with or without intracavitary drug therapy. Successful administration of intracavitary chemotherapy to the upper tracts is impeded by rapid washout of the agent and short dwell times. This has limited the clinical utility of mitomycin C for treatment of upper tract tumors, despite the successful outcomes observed in low-grade urothelial carcinoma of the bladder. Currently, there is an unmet need for development of a technically feasible and oncologically sound intracavitary therapy for management of low-grade UTUC. UGN-101 (Jelmyto™) is a novel formulation of mitomycin C that uses a unique hydrogel designed to increase urinary dwell time, and thereby efficacy of treatment. Preclinical data demonstrated promising results regarding the safety and feasibility of this agent. Preliminary results of a phase III trial (OLYMPUS study) [ClinicalTrials.gov identifier: NCT02793128] demonstrated the efficacy of UGN-101 as a successful chemo-ablative agent for low-grade upper tract tumors. UGN-101 may represent a pivotal paradigm shift in the treatment of low-grade UTUC. Indeed, the drug has recently been granted approval by the US Food and Drug Administration as the first treatment for low-grade UTUC, which may lead to significant improvements in patient care and a long-awaited decrease in the burden of disease.

Keywords: drug development; kidney; upper tract urothelial carcinoma; ureter; urothelial cancer.

Conflict of interest statement

Conflict of interest statement: SFM was a member of the Urogen Scientific Advisory Board (ended January 2019) and is a member of the Taris Bio Scientific Advisory Board. A.K. has no disclosures.

© The Author(s), 2020.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
    1. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73: 111–122.
    1. Foerster B, D’Andrea D, Abufaraj M, et al. >Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature. Urol Oncol. Epub ahead of print 4 March 2019. DOI: 10.1016/j.urolonc.2019.02.004.
    1. Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 2016; 70: 1052–1068.
    1. Yakoubi R, Colin P, Seisen T, et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 2014; 40: 1629–1634.
    1. Kleinmann N, Pierorazio P, Matin S, et al. LBA-25 non-surgical management of low grade upper tract urothelial cancer: an interim analysis of the international multicenter OLYMPUS trial (NCT02793128). J Urol 2018; 199: e1166.
    1. Kleinmann N, Matin S, Pierorazio P, et al. LBA-16 nephron-sparing management of low grade (LG) UTUC with UGN-101 (mitomycin gel) for instillation: the OLYMPUS trial experience. J Urol 2019; 201(Suppl. 4): e999.
    1. Lin JS, Kleinmann N, Wirth GJ, et al. Thermo reversible hydrogel based delivery of mitomycin C for treatment of upper tract urothelial carcinoma (UTUC). J Clin Oncol 2017; 35(Suppl. 15): e16089.
    1. Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol 2020; 21: 776–785.
    1. US Food and Drug Administration. FDA approves first therapy for treatment of low-grade upper tract urothelial cancer, (2020, accessed 15 April 2020).
    1. Donin NM, Duarte S, Lenis AT, et al. Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology 2017; 99: 270–277.
    1. Schmittgen TD, Wientjes MG, Badalament RA, et al. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 1991; 51: 3849–3856.
    1. De Bruijn EA, Sleeboom HP, van Helsdingen PJ, et al. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 1992; 51: 359–364.
    1. Wang AJ, Goldsmith ZG, Neisius A, et al. Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer. J Endourol 2013; 27: 288–293.
    1. Lifschitz D, Meiron M, Konorty M, et al. 25 Hydrogel based drug retention system for the treatment of upper tract urothelial carcinoma. Eur Urol Suppl 2014; 13: e25–e25a.
    1. Colver GB, Inglis JA, McVittie E, et al. Dermatitis due to intravesical mitomycin C: a delayed type hypersensitivity reaction? Br J Dermatol 1990; 122: 217–224.
    1. Nissenkorn I, Herrod H, Soloway MS. Side effects associated with intravesical mitomycin C. J Urol 1981; 126: 596–597.
    1. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, et al. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility. Urol Oncol 2017; 35: 272–278.
    1. Cutress ML, Stewart GD, Wells-Cole S, et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int 2012; 110: 1608–1617.
    1. Keeley FX, Jr, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol 1997; 158: 2074–2077.
    1. Motamedinia P, Keheila M, Leavitt DA, et al. The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol 2016; 30: 262–267.
    1. Aboumarzouk OM, Somani B, Ahmad S, et al. Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann 2013; 5: 184–189.
    1. Metcalfe M, Wagenheim G, Xiao L, et al. Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes. J Endourol 2017; 31: 946–953.
    1. Yossepowitch O, Lifshitz DA, Dekel Y, et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005; 173: 890–893.
    1. Liu Z, Ng J, Yuwono A, et al. Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods. Int Braz J Urol 2017; 43: 1084–1091.
    1. Simhan J, Smaldone MC, Egleston BL, et al. Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 2014; 114: 216–220.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner